Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases

Matthew L. Thomas; Gavin Shaddick; Rachel Charlton; Charlotte Cavill; Richard Holland; Florenzo Iannone; Giovanni Lapadula; Simona Lopriore; Jakub Závada; Michal Uher; Karel Pavelka; Lenka Szczuková; Prodromos Sidiropoulos; Irini Flouri; Alexandros Drosos; Burkhard Möller; Michael J. Nissen; Rüdiger B. Müller; Almut Scherer; Neil McHugh; Alison Nightingale

doi:10.3899/JRHEUM.190815

Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases

Matthew L. Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Florenzo Iannone, Giovanni Lapadula, Simona Lopriore, Jakub Závada, Michal Uher, Karel Pavelka, Lenka Szczuková, Prodromos Sidiropoulos, Irini Flouri, Alexandros Drosos, Burkhard Möller, Michael J. Nissen, Rüdiger B. Müller, Almut Scherer, Neil McHughAlison Nightingale

Department of Mathematics

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	48-57
Number of pages	10
Journal	Journal of Rheumatology
Volume	48
Issue number	1
DOIs	https://doi.org/10.3899/JRHEUM.190815
Publication status	Published - 1 Jan 2021

Keywords

Comparative effectiveness
Drug survival
Methotrexate
Psoriatic arthritis
TNF inhibitor

Access to Document

10.3899/JRHEUM.190815

Cite this

Thomas, M. L., Shaddick, G., Charlton, R., Cavill, C., Holland, R., Iannone, F., Lapadula, G., Lopriore, S., Závada, J., Uher, M., Pavelka, K., Szczuková, L., Sidiropoulos, P., Flouri, I., Drosos, A., Möller, B., Nissen, M. J., Müller, R. B., Scherer, A., ... Nightingale, A. (2021). Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases. Journal of Rheumatology, 48(1), 48-57. https://doi.org/10.3899/JRHEUM.190815

@article{c714168969e947fcaf62dac198a07bd3,

title = "Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases",

keywords = "Comparative effectiveness, Drug survival, Methotrexate, Psoriatic arthritis, TNF inhibitor",

author = "Thomas, {Matthew L.} and Gavin Shaddick and Rachel Charlton and Charlotte Cavill and Richard Holland and Florenzo Iannone and Giovanni Lapadula and Simona Lopriore and Jakub Z{\'a}vada and Michal Uher and Karel Pavelka and Lenka Szczukov{\'a} and Prodromos Sidiropoulos and Irini Flouri and Alexandros Drosos and Burkhard M{\"o}ller and Nissen, {Michael J.} and M{\"u}ller, {R{\"u}diger B.} and Almut Scherer and Neil McHugh and Alison Nightingale",

note = "Funding Information: The study was funded by a nonrestricted investigator-initiated award from Pfizer. 1M.L. Thomas, PhD, Department of Mathematical Science, University of Bath, Bath, UK; 2G. Shaddick, PhD, Department of Mathematics, University of Exeter, Exeter, UK; 3R. Charlton, PhD, N. McHugh, MBChB, MD, FRCP, FRCPath, A. Nightingale, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; 4C. Cavill, BSc, R. Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath, UK; 5F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit—DETO, University of Bari, Bari, Italy; 6J. Z{\'a}vada, MD, PhD, K. Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic; 7M. Uher, MSc, L. Szczukov{\'a}, MD, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; 8P. Sidiropoulos, MD, PhD, I. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece; 9A. Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 10B. M{\"o}ller, Professor, Department of Rheumatology, Immunology & Allergology, Inselspital, University Hospital Bern, Bern, Switzerland; 11M.J. Nissen, MBBS, FRACP, Department of Rheumatology, University Hospital Geneva, Geneva, Switzerland; 12R.B. M{\"u}ller, MD, Cantonal Hospital, Lucerne, Switzerland; 13A. Scherer, PhD, SCQM Foundation, Z{\"u}rich, Switzerland. Funding Information: N. McHugh and A. Nightingale are joint senior authors. NM, AN, RC, MT and CC report grants from Pfizer during the conduct of the study. NM reports personal fees from AbbVie and Lilly and grants from Lilly outside the submitted work. CC reports grants from Celgene, Lilly and Novartis and personal fees from Novartis outside of the submitted work. FI reports personal fees from AbbVie, BMS, Novartis, Pfizer, Lilly, UCB and MSD outside the submitted work. GL reports personal fees from AbbVie, BMS, Novartis, Pfizer, and MSD outside the submitted work. KP reports honoraria for consultations and speaker fees from AbbVie, Pfizer, UCB, Lilly, Novartis, and Roche outside the submitted work. PS reports that the Hellenic Registry for Biologic Therapies was supported in part by the Hellenic Rheumatology Society through unrestricted grants from Schering-Plough, AbbVie, Pfizer, Bristol Myers Squibb, and Roche during the conduct of the study. These companies had no role in study design, collection, analysis, and interpretation of the data and in the writing of the manuscript. PS also reports grants and personal fees from the pharma industry through the University of Crete Special Account for Research, outside the submitted work. Address correspondence to Prof. N. McHugh, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. Email: [email protected]. Accepted for publication March 18, 2020. Publisher Copyright: {\textcopyright} 2021 Journal of Rheumatology. All rights reserved.",

year = "2021",

month = jan,

day = "1",

doi = "10.3899/JRHEUM.190815",

language = "English",

volume = "48",

pages = "48--57",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "1",

}

Thomas, ML, Shaddick, G, Charlton, R, Cavill, C, Holland, R, Iannone, F, Lapadula, G, Lopriore, S, Závada, J, Uher, M, Pavelka, K, Szczuková, L, Sidiropoulos, P, Flouri, I, Drosos, A, Möller, B, Nissen, MJ, Müller, RB, Scherer, A, McHugh, N & Nightingale, A 2021, 'Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases', Journal of Rheumatology, vol. 48, no. 1, pp. 48-57. https://doi.org/10.3899/JRHEUM.190815

TY - JOUR

T1 - Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis

T2 - Combined analysis of european biologics databases

AU - Thomas, Matthew L.

AU - Shaddick, Gavin

AU - Charlton, Rachel

AU - Cavill, Charlotte

AU - Holland, Richard

AU - Iannone, Florenzo

AU - Lapadula, Giovanni

AU - Lopriore, Simona

AU - Závada, Jakub

AU - Uher, Michal

AU - Pavelka, Karel

AU - Szczuková, Lenka

AU - Sidiropoulos, Prodromos

AU - Flouri, Irini

AU - Drosos, Alexandros

AU - Möller, Burkhard

AU - Nissen, Michael J.

AU - Müller, Rüdiger B.

AU - Scherer, Almut

AU - McHugh, Neil

AU - Nightingale, Alison

N1 - Funding Information: The study was funded by a nonrestricted investigator-initiated award from Pfizer. 1M.L. Thomas, PhD, Department of Mathematical Science, University of Bath, Bath, UK; 2G. Shaddick, PhD, Department of Mathematics, University of Exeter, Exeter, UK; 3R. Charlton, PhD, N. McHugh, MBChB, MD, FRCP, FRCPath, A. Nightingale, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; 4C. Cavill, BSc, R. Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath, UK; 5F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit—DETO, University of Bari, Bari, Italy; 6J. Závada, MD, PhD, K. Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic; 7M. Uher, MSc, L. Szczuková, MD, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; 8P. Sidiropoulos, MD, PhD, I. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece; 9A. Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; 10B. Möller, Professor, Department of Rheumatology, Immunology & Allergology, Inselspital, University Hospital Bern, Bern, Switzerland; 11M.J. Nissen, MBBS, FRACP, Department of Rheumatology, University Hospital Geneva, Geneva, Switzerland; 12R.B. Müller, MD, Cantonal Hospital, Lucerne, Switzerland; 13A. Scherer, PhD, SCQM Foundation, Zürich, Switzerland. Funding Information: N. McHugh and A. Nightingale are joint senior authors. NM, AN, RC, MT and CC report grants from Pfizer during the conduct of the study. NM reports personal fees from AbbVie and Lilly and grants from Lilly outside the submitted work. CC reports grants from Celgene, Lilly and Novartis and personal fees from Novartis outside of the submitted work. FI reports personal fees from AbbVie, BMS, Novartis, Pfizer, Lilly, UCB and MSD outside the submitted work. GL reports personal fees from AbbVie, BMS, Novartis, Pfizer, and MSD outside the submitted work. KP reports honoraria for consultations and speaker fees from AbbVie, Pfizer, UCB, Lilly, Novartis, and Roche outside the submitted work. PS reports that the Hellenic Registry for Biologic Therapies was supported in part by the Hellenic Rheumatology Society through unrestricted grants from Schering-Plough, AbbVie, Pfizer, Bristol Myers Squibb, and Roche during the conduct of the study. These companies had no role in study design, collection, analysis, and interpretation of the data and in the writing of the manuscript. PS also reports grants and personal fees from the pharma industry through the University of Crete Special Account for Research, outside the submitted work. Address correspondence to Prof. N. McHugh, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. Email: [email protected]. Accepted for publication March 18, 2020. Publisher Copyright: © 2021 Journal of Rheumatology. All rights reserved.

PY - 2021/1/1

Y1 - 2021/1/1

KW - Comparative effectiveness

KW - Drug survival

KW - Methotrexate

KW - Psoriatic arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85099326525&partnerID=8YFLogxK

U2 - 10.3899/JRHEUM.190815

DO - 10.3899/JRHEUM.190815

M3 - Article

C2 - 32238520

AN - SCOPUS:85099326525

SN - 0315-162X

VL - 48

SP - 48

EP - 57

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 1

ER -

Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: Combined analysis of european biologics databases

Keywords

Access to Document

Other files and links

Cite this